{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:28:23Z","timestamp":1780320503207,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["GSPJS202420"],"award-info":[{"award-number":["GSPJS202420"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["GSPJS202414"],"award-info":[{"award-number":["GSPJS202414"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["GSPJS202417"],"award-info":[{"award-number":["GSPJS202417"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013088","name":"Qinglan Project of Jiangsu Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["22KJA320011"],"award-info":[{"award-number":["22KJA320011"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018636","name":"Xuzhou Science and Technology Program","doi-asserted-by":"publisher","award":["KC22071"],"award-info":[{"award-number":["KC22071"]}],"id":[{"id":"10.13039\/501100018636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bcp.2025.116998","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:30:56Z","timestamp":1748111456000},"page":"116998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1"],"prefix":"10.1016","volume":"239","author":[{"given":"Yaxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-7719","authenticated-orcid":false,"given":"Ruosi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4314\/gmj.v53i1.8","article-title":"Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases","volume":"53","author":"Acquah","year":"2019","journal-title":"Ghana Med. J."},{"key":"10.1016\/j.bcp.2025.116998_b0015","doi-asserted-by":"crossref","unstructured":"J. Liu, W. Liu, L. Mi, X. Zeng, C. Cai, J. Ma, L. Wang, Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016, 12(1) (2019) 136.","DOI":"10.1186\/s13045-019-0807-5"},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","article-title":"The role of m6A RNA methylation in cancer metabolism","volume":"21","author":"An","year":"2022","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2025.116998_b0025","first-page":"467","article-title":"m6A RNA Methylation: Ramifications for Gene Expression and Human","volume":"62","author":"Karthiya","year":"2020","journal-title":"Health"},{"key":"10.1016\/j.bcp.2025.116998_b0030","doi-asserted-by":"crossref","unstructured":"S. Ma, C. Chen, X. Ji, J. Liu, Q. Zhou, G. Wang, W. Yuan, Q. Kan, Z. Sun, The interplay between m6A RNA methylation and noncoding RNA in cancer, 12(1) (2019) 121.","DOI":"10.1186\/s13045-019-0805-7"},{"key":"10.1016\/j.bcp.2025.116998_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108613","article-title":"The role of m6A RNA methylation in cancer","volume":"112","author":"Sun","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2025.116998_b0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1042\/BST20230574","article-title":"RNA m6A modification, signals for degradation or stabilisation?","volume":"52","author":"Wei","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2025.116998_b0045","doi-asserted-by":"crossref","unstructured":"C. Zhang, N. Liu, N6-methyladenosine (m6A) modification in gynecological malignancies, 237(9) (2022) 3465-3479.","DOI":"10.1002\/jcp.30828"},{"key":"10.1016\/j.bcp.2025.116998_b0050","doi-asserted-by":"crossref","unstructured":"L. Bai, Y. Xiang, M. Tang, S. Liu, Q. Chen, Q. Chen, M. Zhang, ALKBH5 controls the meiosis-coupled mRNA clearance in oocytes by removing the N\u2009(6)-methyladenosine methylation, 14(1) (2023) 6532.","DOI":"10.1038\/s41467-023-42302-6"},{"key":"10.1016\/j.bcp.2025.116998_b0055","doi-asserted-by":"crossref","unstructured":"J. Qu, Y. Hou, Q. Chen, J. Chen, Y. Li, E. Zhang, H. Gu, R. Xu, Y. Liu, W. Cao, J. Zhang, L. Cao, J. He, Z. Cai, RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-\u03baB and MAPK signaling pathways, 41(3) (2022) 400-413.","DOI":"10.1038\/s41388-021-02095-8"},{"key":"10.1016\/j.bcp.2025.116998_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107451","article-title":"Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5","volume":"141","author":"Zhu","year":"2024","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.116998_b0065","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.7150\/ijbs.64943","article-title":"ALKBH5 promotes multiple myeloma tumorigenicity through inducing m(6)A-demethylation of SAV1 mRNA and myeloma stem cell phenotype","volume":"18","author":"Yu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","article-title":"Regulation of the master regulator FOXM1 in cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.bcp.2025.116998_b0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/leu.2015.334","article-title":"FOXM1 is a therapeutic target for high-risk multiple myeloma","volume":"30","author":"Gu","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2025.116998_b0080","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","article-title":"FOXM1 in cancer: interactions and vulnerabilities","volume":"77","author":"Gartel","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.116998_b0085","doi-asserted-by":"crossref","unstructured":"C. Gu, X. Jing, C. Holman, R. Sompallae, F. Zhan, G. Tricot, Y. Yang, S. Janz, Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma, 18(1) (2018) 1152.","DOI":"10.1186\/s12885-018-5015-0"},{"key":"10.1016\/j.bcp.2025.116998_b0090","doi-asserted-by":"crossref","unstructured":"J.H. Tang, L. Yang, J.X. Chen, Q.R. Li, L.R. Zhu, Q.F. Xu, G.H. Huang, Z.X. Zhang, Y. Xiang, L. Du, Z. Zhou, S.Q. Lv, Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis, 39(1) (2019) 81.","DOI":"10.1186\/s40880-019-0424-2"},{"issue":"4","key":"10.1016\/j.bcp.2025.116998_b0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccell.2017.02.013","article-title":"m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2025.116998_b0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41388-021-02095-8","article-title":"RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-kappaB and MAPK signaling pathways","volume":"41","author":"Qu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.116998_b0105","doi-asserted-by":"crossref","unstructured":"F. Yu, J. Wei, Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response, 49(10) (2021) 5779-5797.","DOI":"10.1093\/nar\/gkab415"},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.116998_b0115","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.18632\/oncotarget.6601","article-title":"Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib","volume":"7","author":"Hui","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","article-title":"The role of m6A methylation in therapy resistance in cancer","volume":"22","author":"Zhuang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116998_b0125","doi-asserted-by":"crossref","unstructured":"H. Yin, X. Zhang, P. Yang, X. Zhang, Y. Peng, D. Li, Y. Yu, Y. Wu, Y. Wang, J. Zhang, X. Ding, X. Wang, A. Yang, RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming, 12(1) (2021) 1394.","DOI":"10.1038\/s41467-021-21514-8"},{"key":"10.1016\/j.bcp.2025.116998_b0130","doi-asserted-by":"crossref","unstructured":"Q. Lan, P.Y. Liu, J.L. Bell, The Emerging Roles of RNA m(6)A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance, 81(13) (2021) 3431-3440.","DOI":"10.1158\/0008-5472.CAN-20-4107"},{"issue":"2","key":"10.1016\/j.bcp.2025.116998_b0135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2025.116998_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2025.116998_b0145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.tplants.2015.07.005","article-title":"Histone acetylation enzymes coordinate metabolism and gene expression","volume":"20","author":"Shen","year":"2015","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.bcp.2025.116998_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0155","article-title":"Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer","volume":"1878","author":"He","year":"2023","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2025.116998_b0160","doi-asserted-by":"crossref","unstructured":"P. Miziak, M. Baran, L. Borkiewicz, T. Trombik, Acetylation of histone H3 in cancer progression and prognosis, 25(20) (2024).","DOI":"10.3390\/ijms252010982"},{"key":"10.1016\/j.bcp.2025.116998_b0165","doi-asserted-by":"crossref","unstructured":"A. Zhuang, X. Gu, T. Ge, S. Wang, S. Ge, P. Chai, Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m(6) A RNA methylation in ocular melanoma, 43(11) (2023) 1185-1206.","DOI":"10.1002\/cac2.12471"},{"issue":"1","key":"10.1016\/j.bcp.2025.116998_b0170","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-022-02460-9","article-title":"YTHDC1 is downregulated by the YY1\/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway","volume":"41","author":"Li","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116998_b0175","doi-asserted-by":"crossref","unstructured":"Z. Yang, W. Su, Q. Zhang, L. Niu, B. Feng, Y. Zhang, F. Huang, J. He, Q. Zhou, X. Zhou, L. Ma, J. Zhou, Y. Wang, W. Xiong, J. Xiang, Z. Hu, Q. Zhan, B. Yao, Lactylation of HDAC1 confers resistance to ferroptosis in colorectal cancer, Adv. Sci. (2025) e2408845.","DOI":"10.1002\/advs.202408845"},{"issue":"2","key":"10.1016\/j.bcp.2025.116998_b0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1381612823666171114165051","article-title":"Curcumin: A natural Pan-HDAC inhibitor in cancer","volume":"24","author":"Soflaei","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.bcp.2025.116998_b0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3892\/ol.2014.2714","article-title":"HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review)","volume":"9","author":"Ni","year":"2015","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.bcp.2025.116998_b0190","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2146\/ajhp120163","article-title":"Romidepsin for the treatment of T-cell lymphomas","volume":"70","author":"McGraw","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.bcp.2025.116998_b0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2015.03.016","article-title":"Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma","volume":"364","author":"Shin","year":"2015","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bcp.2025.116998_b0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","article-title":"Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells","volume":"68","author":"Karthik","year":"2014","journal-title":"Biomed. Pharmacother."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:24:09Z","timestamp":1762097049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225002618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S0006295225002618"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116998","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116998"}}